COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Gladstone Investment Announces Retirement of Chief Operating Officer Terry Lee Brubaker
Gladstone Investment Corporation announces retirement of COO Terry Lee Brubaker. Michael LiCalsi to take on additional responsibilities. National search for Chief Investment Officer initiated -
-
COMMUNIQUÉ DE PRESSE
Gladstone Commercial Corporation Announces Retirement of Chief Operating Officer Terry Lee Brubaker
Gladstone Commercial Corporation announces retirement of Chief Operating Officer Terry Lee Brubaker. Michael LiCalsi to take on additional responsibilities. Company conducting search for new Chief Investment Officer -
-
COMMUNIQUÉ DE PRESSE
New to the Street to Showcase Innovators in Electric Vehicles, Water Solutions, Environmental Conservation, and Cybersecurity on Fox Business: Episode 612 Airs Monday, November 18 at 10:30 PM PST
New to The Street announces Episode 612 featuring exclusive interviews with leaders in electric vehicles, sustainable water solutions, environmental conservation, and secure communications airing on Fox Business. Insights on technology, sustainability, and cybersecurity -
COMMUNIQUÉ DE PRESSE
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
Inventiva presents positive results from Phase 2 study on lanifibranor and empagliflozin combination therapy for MASH and T2D patients at AASLD The Liver Meeting® 2024 -
COMMUNIQUÉ DE PRESSE
Inventiva présentera lors de la session « late-breaker » de l'AASLD The Liver Meeting®, les résultats de l'analyse finale de la Phase 2 évaluant la combinaison de lanifibranor avec empagliflozine chez des patients atteints de MASH et DT2
Inventiva présente les résultats de l'étude LEGEND sur lanifibranor et empagliflozine pour MASH et diabète de type 2 à l'AASLD The Liver Meeting®. Améliorations notables notamment sur HbA1c, stéatose hépatique et santé cardiométabolique -
-
